A high-quality, profitable business with growing sales.
Facts from SEC filings, not a recommendation.
From UROY's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Move the sliders to your own view of UROY. Starting points are the company's recent numbers.
What today's price needs: with a 22% margin and a 32x P/E, sales could shrink about 0.5% a year for 5 years and still match today's price.
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.
Price chart by TradingView.
From annual reports filed with the SEC. Gross margin doesn't apply to banks and insurers, so it isn't scored. Not in this company's SEC data, so not scored: profitable every year, share count not growing. A checklist is a starting point for research, not a verdict.
No open-market insider buys or sells in the last 90 days.
No trades to chart yet.
SEC filings of any kind. 50 means a normal week.
Institutions held almost none of it the quarter before (new listing, spin-off or ticker change), so there's no fair percent change yet. 4 bought, 0 sold.
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
13,850 shares at $3.13 avg ($3.12 to $3.13) · $43K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page